We have located links that may give you full text access.
Imatinib Mesylate Induced Erythroderma.
Journal of the Association of Physicians of India 2018 December
Imatinib, a specific tyrosine kinase inhibitor is a new anticancer agent, which has shown excellent efficacy in managing chronic myeloid leukemia. It is well tolerated with few side effects. Commonest adverse events are maculopapular eruptions and periorbital edema were reported. Severe adverse reactions are seen in 5% of patients. Exfoliative dermatitis has been very rarely reported with this drug. We report a case of a 55-year-old female who initially presented with a maculopapular rash and developed erythroderma on continuation of the drug.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app